We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
OPKO Health, Inc. (OPK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.2850 |
| Open | 1.2600 |
| Bid | 1.2300 x 300 |
| Ask | 1.2400 x 300 |
| Day's Range | 1.2100 - 1.2666 |
| 52 Week Range | 0.8500 - 2.2400 |
| Volume | |
| Avg. Volume | 9,676,106 |
| Market Cap | 857.3M |
| Beta (5Y Monthly) | 1.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2500 |
| Earnings Date | May 01, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.25 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for OPK
Related Research
- Opko Health, Inc.Daily – Vickers Top Insider Picks for 03/15/2024The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.RatingFair ValueEconomic Moatlast monthArgus Research
ZacksOPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
- Zacks
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
MedTech DiveLabcorp inks $237.5M buyout of Opko’s reproductive, women’s health testing assets
The acquired assets generate about $100 million in annual revenue, according to the deal announcement.
PR NewswireLabcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health, Inc. (Nasdaq: OPK), a multinational biopharmaceutical and diagnostics company, announced today that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.
ZacksOPKO Health (OPK) And Entera Bio Announce Data for GLP-2
OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
GlobeNewswireEntera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15) JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2 agonist developed by OPKO Health, Inc. (Nasdaq: “OPK”, or “OPKO”) with En
GlobeNewswireAIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal antibodies and minimal anti-drug antibodies WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency v
Simply Wall St.Analysts Have Lowered Expectations For OPKO Health, Inc. (NASDAQ:OPK) After Its Latest Results
Investors in OPKO Health, Inc. ( NASDAQ:OPK ) had a good week, as its shares rose 3.1% to close at US$1.00 following...
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript February 27, 2024 OPKO Health, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
Simply Wall St.OPKO Health Full Year 2023 Earnings: EPS Beats Expectations
OPKO Health ( NASDAQ:OPK ) Full Year 2023 Results Key Financial Results Revenue: US$863.5m (down 14% from FY 2022). Net...
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| INO Inovio Pharmaceuticals, Inc. | |||
| VXRT Vaxart, Inc. | |||
| CODX Co-Diagnostics, Inc. | |||
| IBIO iBio, Inc. | |||
| VBIV VBI Vaccines Inc. |
Similar to OPK
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| LH Laboratory Corporation of America Holdings | |||
| NEOG Neogen Corporation | |||
| EXAS Exact Sciences Corporation | |||
| OCX OncoCyte Corporation | |||
| GH Guardant Health, Inc. |
Analyst Price Targets (6)
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/3/2024 | |
| Maintains | Barrington Research: Outperform to Outperform | 4/1/2024 | |
| Reiterates | Piper Sandler: Overweight to Overweight | 4/1/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/28/2024 | |
| Maintains | Barrington Research: Outperform to Outperform | 2/28/2024 | |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/7/2023 |
Company Profile
4400 Biscayne Boulevard
Miami, FL 33137
United States
305 575 4100
https://www.opko.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 3,930
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
